레보도파 시장 : 형태별, 투여 경로별, 유통 채널별 - 세계 기회 분석과 산업 예측(2023-2032년)

Levodopa Market By Form, By Route of Administration, By Distribution Channels : Global Opportunity Analysis and Industry Forecast, 2023-2032

US $ 5,730 ￦ 7,891,000

PDF (Business License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄는 5회 가능하며, 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다. 2명 이상이 이용할 경우, 추가 요금을 지불하여 라이선스 업그레이드로 최대 5명까지 이용 가능합니다.

US $ 9,600 ￦ 13,221,000

PDF (Enterprise User License) & Excel (Data Pack) & Free Update

PDF 보고서 및 Excel 데이터를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다. 보고서 업데이트 서비스가 무료로 제공됩니다.

한글목차

세계의 레보도파 시장은 2023-2032년 CAGR 6.1%로 2022년 16억 5,540만 달러에서 성장하며, 2032년까지 29억 3,460만 달러에 달할 것으로 예측됩니다.

레보도파는 일반적으로 L-도파라고 불리며 체내에서 도파민으로 전환되는 화학 성분입니다. 도파민은 뇌에서 분비되는 화학 전달 물질입니다. 도파민은 쾌락, 뇌 기능 및 기억 과정을 촉진합니다. 거의 모든 환자는 파킨슨병(PD)의 초기 단계에서 도파민 전구체인 레보도파를 투여받으며, 이는 파킨슨병의 증상을 효과적으로 조절합니다. 카르비도파는 종종 레보도파 함유 약물과 함께 사용되며, 도파민 대사를 감소시켜 그 효과를 향상시킵니다.

레보도파 시장은 의료 인프라에 대한 투자 증가, 가처분 소득 증가, 신흥 시장에서의 의료 접근성 증가로 인해 괄목할 만한 성장을 보이고 있습니다. 또한 신흥 국가들이 의료 시스템을 강화함에 따라 파킨슨병 관리를 위한 레보도파와 같은 약물의 가용성과 가격이 상승하고 있습니다. 의료 서비스에 대한 접근성이 개선되면 진단율과 치료 시작률도 높아져 레보도파 수요를 견인할 것입니다. 또한 가처분 소득 증가는 개인에게 필수 의약품을 구매할 수 있는 여유를 제공함으로써 시장 성장을 가속할 것입니다. 또한 이러한 요인들이 복합적으로 작용하여 환자층이 확대될 뿐만 아니라 레보도파 시장에 진출한 제약사들, 특히 의료 인프라가 발달한 지역에서 새로운 성장 기회를 창출할 수 있습니다. 그러나 레보도파와 관련된 높은 비용은 레보도파 시장의 성장을 저해하는 주요 요인 중 하나입니다. 또한 특히 의료 자원이 제한된 지역과 저소득층에서는 파킨슨병 관리를 위한 이 중요한 약물에 대한 환자들의 접근성을 제한하고 있습니다. 또한 레보도파의 경제적 문제로 인해 환자들이 일관된 치료를 받거나 처방된 요법을 준수하지 못해 질병 관리 결과가 최적이 아닌 결과를 초래할 수 있습니다. 또한 높은 비용은 의료기관의 예산을 압박하고 상환 옵션을 제한하여 시장 성장을 저해할 수 있습니다. 또한 레보도파에 대한 공평한 접근성을 보장하고 시장 성장과 환자 치료에 미치는 영향을 완화하기 위해서는 가격 장벽을 해결하는 것이 필수적입니다.

반대로, 약물전달 시스템의 기술 발전은 혁신적인 제형과 대체 투여 경로를 통해 레보도파의 효능과 환자 순응도를 향상시켜 시장 성장을 가속할 것으로 예상됩니다. 또한 특히 신흥 국가 지역의 의료비 지출 증가는 레보도파에 대한 접근성을 높이고 시장 성장을 가속할 것입니다. 또한 신흥 시장은 노인 인구 증가와 함께 시장 침투의 미개척 잠재력을 제공합니다. 또한 새로운 제형과 병용요법을 모색하는 지속적인 연구 구상과 채널 개발은 레보도파 시장 전망을 강화하고 있습니다. 또한 지원적인 의료 정책 및 상환 프레임워크는 광범위한 접근성을 보장하고, 질병 인식 및 진단율 증가는 시장 성장에 기여할 것으로 예상됩니다.

이해관계자 주요 이점

• 이 보고서는 2022-2032년 레보도파 시장 분석 시장 부문, 현재 동향, 추정 및 동향, 역학을 정량적으로 분석하여 레보도파 시장의 유력한 기회를 식별합니다.
• 시장 성장 촉진요인, 시장 성장 억제요인, 시장 기회와 관련된 정보와 함께 시장 조사를 제공합니다.
• Porter의 다섯 가지 힘 분석은 이해 관계자가 이익 중심의 비즈니스 결정을 내리고 공급업체와 구매자 네트워크를 강화할 수 있도록 구매자와 공급업체의 힘을 강조합니다.
• 레보도파 시장 세분화에 대한 상세한 분석은 시장 기회를 결정하는 데 도움이 될 것입니다.
• 각 지역의 주요 국가는 세계 시장에 대한 매출 기여도에 따라 매핑되어 있습니다.
• 시장 기업의 포지셔닝은 벤치마킹을 용이하게 하고 시장 기업의 현재 위치에 대한 명확한 이해를 제공합니다.
• 이 보고서에는 지역 및 세계 레보도파 시장 동향, 주요 기업, 시장 부문, 용도 및 시장 성장 전략에 대한 분석이 포함되어 있습니다.

이 보고서에서 가능한 커스터마이징(추가 비용 및 일정이 있습니다.)

• 제품에 포함된 원재료 분석(%별)
• 투자 기회
• 기술 동향 분석
• 제품/부문별 기업 시장 세분화 분석
• 주요 기업의 신제품 개발/ 제품 매트릭스
• 규제 가이드라인
• 고객의 관심사에 따른 추가 기업 개요
• 국가별 또는 지역별 추가 분석 - 시장 규모 및 예측
• 크리스크로스 부문 분석 - 시장 규모 및 예측
• 기업 개요 확장 리스트
• 과거 시장 데이터
• 주요 기업의 세부 정보(위치, 연락처, 공급업체/벤더 네트워크 등 포함, 엑셀 형식)
• 고객/소비자/원료 공급업체 리스트 - 밸류체인 분석
• 세계/지역/국가별 기업의 시장 점유율 분석

목차

제1장 서론

제2장 주요 요약

제3장 시장 개요

• 시장의 정의와 범위
• 주요 조사 결과
  • 영향요인
  • 주요 투자 기회
• Porter's Five Forces 분석
• 시장 역학
  • 촉진요인
  • 억제요인
  • 기회
• 평균 판매 가격
• 시장 점유율 분석
• 브랜드 점유율 분석
• 무역 데이터 분석
• 제품 소비
• 밸류체인 분석
• 규제 가이드라인
• 주요 규제 분석
• 상환 시나리오
• 특허 상황

제4장 레보도파 시장 : 형태별

• 개요
• 정제
• 캡슐
• 분말
• 액체

제5장 레보도파 시장 : 투여 경로별

• 개요
• 경구
• 비경구

제6장 레보도파 시장 : 유통 채널별

• 개요
• 병원 약국
• 소매 약국
• 온라인 약국
• 기타

제7장 레보도파 시장 : 지역별

• 개요
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 독일
  • 영국
  • 프랑스
  • 스페인
  • 이탈리아
  • 기타
• 아시아태평양
  • 중국
  • 일본
  • 인도
  • 한국
  • 호주
  • 기타
• 라틴아메리카·중동 및 아프리카
  • 브라질
  • 사우디아라비아
  • 아랍에미리트
  • 남아프리카공화국
  • 기타

제8장 경쟁 상황

• 서론
• 주요 성공 전략
• 주요 10사의 제품 매핑
• 경쟁 대시보드
• 경쟁 히트맵
• 주요 기업의 포지셔닝, 2022년

제9장 기업 개요

• Novartis AG
• Merck and Co. Inc.
• Eli Lilly and Company
• Bristol-Myers Squibb Co.
• Teva Pharmaceutical Industries Ltd.
• Impax Laboratories Inc.
• Pfizer Inc.
• UCB SA
• Sun Pharmaceutical Industries Ltd.
• Mylan Nv

KSA

영문 목차

영문목차

The global levodopa market is anticipated to reach $2,934.6 million by 2032, growing from $1,655.4 million in 2022 at a CAGR of 6.1% from 2023 to 2032.

Levodopa, commonly called L-Dopa, is a chemical building block converted into dopamine in the body. Dopamine is a chemical messenger secreted in the brain. It facilitates pleasure, brain function, and memory processes. Almost all patients get levodopa, a dopamine precursor that effectively controls Parkinson's disease (PD) symptoms in its early stages. Carbidopa is frequently used in combination with levodopa-containing medications to increase their efficacy by decreasing dopamine metabolism.

The levodopa market has been witnessing significant growth, owing to rise in investments in healthcare infrastructure, increase in disposable income, and surge in healthcare access in emerging markets. Moreover, as emerging economies bolster their healthcare systems, increase in availability and affordability of medications such as levodopa for Parkinson's disease management. Improved access to healthcare services translates into greater diagnosis rates and treatment initiation, consequently driving the demand for levodopa. Furthermore, increase in disposable income empowers individuals to afford essential medications, driving the market growth. In addition, the combination of these factors not only expands the patient pool but also creates new growth opportunities for pharmaceutical companies operating in the levodopa market, particularly in regions with evolving healthcare infrastructures. However, high cost associated with levodopa is one of the key factors restraining the growth of the levodopa market. Moreover, affordability issues limit patient access to this crucial medication for Parkinson's disease management, particularly in regions with limited healthcare resources and low-income populations. Furthermore, the financial problem of levodopa prevents patients from seeking consistent treatment or adhering to prescribed regimens, leading to suboptimal disease management outcomes. In addition, the high cost may strain healthcare budgets and limit reimbursement options, restraining market growth. Moreover, addressing the affordability barrier is imperative to ensure equitable access to levodopa and mitigate its impact on market growth and patient care.

On the contrary, increase in technological advancements in drug delivery systems promise to enhance levodopa's efficacy and patient adherence through innovative formulations and alternative administration routes are expected to drive the market growth. Furthermore, rise in healthcare expenditure, especially in developing regions, facilitates greater accessibility to levodopa, driving the market growth. In addition, emerging markets, coupled with increase in geriatric population, offer untapped potential for market penetration. Moreover, ongoing research initiatives and channel developments exploring novel formulations and combination therapies bolster levodopa's market prospects. Furthermore, supportive healthcare policies and reimbursement frameworks ensure widespread accessibility, while increase in disease awareness and diagnosis rates contribute to the market growth.

The key players operating in the levodopa market include Novartis AG, Merck & Co. Inc., Eli Lilly & Company, Bristol-Myers Squibb Co., Teva Pharmaceutical Industries Ltd., Impax Laboratories Inc., Pfizer Inc., UCB SA, Sun Pharmaceutical Industries Ltd., and Mylan NV. In addition, the market players are increasingly focusing on adopting strategies such as collaborations and acquisitions to gain a competitive edge in the market.

Key Benefits For Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the levodopa market analysis from 2022 to 2032 to identify the prevailing levodopa market opportunities.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the levodopa market segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global levodopa market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

• Quarterly Update and* (only available with a corporate license, on listed price)
• 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
• Free Upcoming Version on the Purchase of Five and Enterprise User License.
• 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
• 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
• Free data Pack on the Five and Enterprise User License. (Excel version of the report)
• Free Updated report if the report is 6-12 months old or older.
• 24-hour priority response*
• Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

• Analysis of raw material in a product (by %)
• Investment Opportunities
• Technology Trend Analysis
• Market share analysis of players by products/segments
• New Product Development/ Product Matrix of Key Players
• Regulatory Guidelines
• Additional company profiles with specific to client's interest
• Additional country or region analysis- market size and forecast
• Criss-cross segment analysis- market size and forecast
• Expanded list for Company Profiles
• Historic market data
• Key player details (including location, contact details, supplier/vendor network etc. in excel format)
• List of customers/consumers/raw material suppliers- value chain analysis
• Market share analysis of players at global/region/country level

Key Market Segments

By Form

• Tablets
• Capsules
• Powder
• Liquid

By Route of Administration

• Oral
• Parenteral

By Distribution Channels

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Other

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia-Pacific
• LAMEA
  • Brazil
  • Saudi Arabia
  • United Arab Emirates
  • South Africa
  • Rest of LAMEA

Key Market Players:

• Novartis AG
• Merck and Co. Inc.
• Eli Lilly and Company
• Bristol-Myers Squibb Co.
• Teva Pharmaceutical Industries Ltd.
• Impax Laboratories Inc.
• Pfizer Inc.
• UCB SA
• Sun Pharmaceutical Industries Ltd.
• Mylan Nv

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

• 1.1. Report description
• 1.2. Key market segments
• 1.3. Key benefits to the stakeholders
• 1.4. Research methodology
  • 1.4.1. Primary research
  • 1.4.2. Secondary research
  • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

• 2.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

• 3.1. Market definition and scope
• 3.2. Key findings
  • 3.2.1. Top impacting factors
  • 3.2.2. Top investment pockets
• 3.3. Porter's five forces analysis
• 3.4. Market dynamics
  • 3.4.1. Drivers
  • 3.4.2. Restraints
  • 3.4.3. Opportunities
• 3.5. Average Selling Price
• 3.6. Market Share Analysis
• 3.7. Brand Share Analysis
• 3.8. Trade Data Analysis
• 3.9. Product Consumption
• 3.10. Value Chain Analysis
• 3.11. Regulatory Guidelines
• 3.12. Key Regulation Analysis
• 3.13. Reimbursement Scenario
• 3.14. Patent Landscape

CHAPTER 4: LEVODOPA MARKET, BY FORM

• 4.1. Overview
  • 4.1.1. Market size and forecast
• 4.2. Tablets
  • 4.2.1. Key market trends, growth factors and opportunities
  • 4.2.2. Market size and forecast, by region
  • 4.2.3. Market share analysis by country
• 4.3. Capsules
  • 4.3.1. Key market trends, growth factors and opportunities
  • 4.3.2. Market size and forecast, by region
  • 4.3.3. Market share analysis by country
• 4.4. Powder
  • 4.4.1. Key market trends, growth factors and opportunities
  • 4.4.2. Market size and forecast, by region
  • 4.4.3. Market share analysis by country
• 4.5. Liquid
  • 4.5.1. Key market trends, growth factors and opportunities
  • 4.5.2. Market size and forecast, by region
  • 4.5.3. Market share analysis by country

CHAPTER 5: LEVODOPA MARKET, BY ROUTE OF ADMINISTRATION

• 5.1. Overview
  • 5.1.1. Market size and forecast
• 5.2. Oral
  • 5.2.1. Key market trends, growth factors and opportunities
  • 5.2.2. Market size and forecast, by region
  • 5.2.3. Market share analysis by country
• 5.3. Parenteral
  • 5.3.1. Key market trends, growth factors and opportunities
  • 5.3.2. Market size and forecast, by region
  • 5.3.3. Market share analysis by country

CHAPTER 6: LEVODOPA MARKET, BY DISTRIBUTION CHANNELS

• 6.1. Overview
  • 6.1.1. Market size and forecast
• 6.2. Hospital Pharmacies
  • 6.2.1. Key market trends, growth factors and opportunities
  • 6.2.2. Market size and forecast, by region
  • 6.2.3. Market share analysis by country
• 6.3. Retail Pharmacies
  • 6.3.1. Key market trends, growth factors and opportunities
  • 6.3.2. Market size and forecast, by region
  • 6.3.3. Market share analysis by country
• 6.4. Online Pharmacies
  • 6.4.1. Key market trends, growth factors and opportunities
  • 6.4.2. Market size and forecast, by region
  • 6.4.3. Market share analysis by country
• 6.5. Other
  • 6.5.1. Key market trends, growth factors and opportunities
  • 6.5.2. Market size and forecast, by region
  • 6.5.3. Market share analysis by country

CHAPTER 7: LEVODOPA MARKET, BY REGION

• 7.1. Overview
  • 7.1.1. Market size and forecast By Region
• 7.2. North America
  • 7.2.1. Key market trends, growth factors and opportunities
  • 7.2.2. Market size and forecast, by Form
  • 7.2.3. Market size and forecast, by Route of Administration
  • 7.2.4. Market size and forecast, by Distribution Channels
  • 7.2.5. Market size and forecast, by country
    • 7.2.5.1. U.S.
    • 7.2.5.1.1. Market size and forecast, by Form
    • 7.2.5.1.2. Market size and forecast, by Route of Administration
    • 7.2.5.1.3. Market size and forecast, by Distribution Channels
    • 7.2.5.2. Canada
    • 7.2.5.2.1. Market size and forecast, by Form
    • 7.2.5.2.2. Market size and forecast, by Route of Administration
    • 7.2.5.2.3. Market size and forecast, by Distribution Channels
    • 7.2.5.3. Mexico
    • 7.2.5.3.1. Market size and forecast, by Form
    • 7.2.5.3.2. Market size and forecast, by Route of Administration
    • 7.2.5.3.3. Market size and forecast, by Distribution Channels
• 7.3. Europe
  • 7.3.1. Key market trends, growth factors and opportunities
  • 7.3.2. Market size and forecast, by Form
  • 7.3.3. Market size and forecast, by Route of Administration
  • 7.3.4. Market size and forecast, by Distribution Channels
  • 7.3.5. Market size and forecast, by country
    • 7.3.5.1. Germany
    • 7.3.5.1.1. Market size and forecast, by Form
    • 7.3.5.1.2. Market size and forecast, by Route of Administration
    • 7.3.5.1.3. Market size and forecast, by Distribution Channels
    • 7.3.5.2. UK
    • 7.3.5.2.1. Market size and forecast, by Form
    • 7.3.5.2.2. Market size and forecast, by Route of Administration
    • 7.3.5.2.3. Market size and forecast, by Distribution Channels
    • 7.3.5.3. France
    • 7.3.5.3.1. Market size and forecast, by Form
    • 7.3.5.3.2. Market size and forecast, by Route of Administration
    • 7.3.5.3.3. Market size and forecast, by Distribution Channels
    • 7.3.5.4. Spain
    • 7.3.5.4.1. Market size and forecast, by Form
    • 7.3.5.4.2. Market size and forecast, by Route of Administration
    • 7.3.5.4.3. Market size and forecast, by Distribution Channels
    • 7.3.5.5. Italy
    • 7.3.5.5.1. Market size and forecast, by Form
    • 7.3.5.5.2. Market size and forecast, by Route of Administration
    • 7.3.5.5.3. Market size and forecast, by Distribution Channels
    • 7.3.5.6. Rest of Europe
    • 7.3.5.6.1. Market size and forecast, by Form
    • 7.3.5.6.2. Market size and forecast, by Route of Administration
    • 7.3.5.6.3. Market size and forecast, by Distribution Channels
• 7.4. Asia-Pacific
  • 7.4.1. Key market trends, growth factors and opportunities
  • 7.4.2. Market size and forecast, by Form
  • 7.4.3. Market size and forecast, by Route of Administration
  • 7.4.4. Market size and forecast, by Distribution Channels
  • 7.4.5. Market size and forecast, by country
    • 7.4.5.1. China
    • 7.4.5.1.1. Market size and forecast, by Form
    • 7.4.5.1.2. Market size and forecast, by Route of Administration
    • 7.4.5.1.3. Market size and forecast, by Distribution Channels
    • 7.4.5.2. Japan
    • 7.4.5.2.1. Market size and forecast, by Form
    • 7.4.5.2.2. Market size and forecast, by Route of Administration
    • 7.4.5.2.3. Market size and forecast, by Distribution Channels
    • 7.4.5.3. India
    • 7.4.5.3.1. Market size and forecast, by Form
    • 7.4.5.3.2. Market size and forecast, by Route of Administration
    • 7.4.5.3.3. Market size and forecast, by Distribution Channels
    • 7.4.5.4. South Korea
    • 7.4.5.4.1. Market size and forecast, by Form
    • 7.4.5.4.2. Market size and forecast, by Route of Administration
    • 7.4.5.4.3. Market size and forecast, by Distribution Channels
    • 7.4.5.5. Australia
    • 7.4.5.5.1. Market size and forecast, by Form
    • 7.4.5.5.2. Market size and forecast, by Route of Administration
    • 7.4.5.5.3. Market size and forecast, by Distribution Channels
    • 7.4.5.6. Rest of Asia-Pacific
    • 7.4.5.6.1. Market size and forecast, by Form
    • 7.4.5.6.2. Market size and forecast, by Route of Administration
    • 7.4.5.6.3. Market size and forecast, by Distribution Channels
• 7.5. LAMEA
  • 7.5.1. Key market trends, growth factors and opportunities
  • 7.5.2. Market size and forecast, by Form
  • 7.5.3. Market size and forecast, by Route of Administration
  • 7.5.4. Market size and forecast, by Distribution Channels
  • 7.5.5. Market size and forecast, by country
    • 7.5.5.1. Brazil
    • 7.5.5.1.1. Market size and forecast, by Form
    • 7.5.5.1.2. Market size and forecast, by Route of Administration
    • 7.5.5.1.3. Market size and forecast, by Distribution Channels
    • 7.5.5.2. Saudi Arabia
    • 7.5.5.2.1. Market size and forecast, by Form
    • 7.5.5.2.2. Market size and forecast, by Route of Administration
    • 7.5.5.2.3. Market size and forecast, by Distribution Channels
    • 7.5.5.3. United Arab Emirates
    • 7.5.5.3.1. Market size and forecast, by Form
    • 7.5.5.3.2. Market size and forecast, by Route of Administration
    • 7.5.5.3.3. Market size and forecast, by Distribution Channels
    • 7.5.5.4. South Africa
    • 7.5.5.4.1. Market size and forecast, by Form
    • 7.5.5.4.2. Market size and forecast, by Route of Administration
    • 7.5.5.4.3. Market size and forecast, by Distribution Channels
    • 7.5.5.5. Rest of LAMEA
    • 7.5.5.5.1. Market size and forecast, by Form
    • 7.5.5.5.2. Market size and forecast, by Route of Administration
    • 7.5.5.5.3. Market size and forecast, by Distribution Channels

CHAPTER 8: COMPETITIVE LANDSCAPE

• 8.1. Introduction
• 8.2. Top winning strategies
• 8.3. Product mapping of top 10 player
• 8.4. Competitive dashboard
• 8.5. Competitive heatmap
• 8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

• 9.1. Novartis AG
  • 9.1.1. Company overview
  • 9.1.2. Key executives
  • 9.1.3. Company snapshot
• 9.2. Merck and Co. Inc.
  • 9.2.1. Company overview
  • 9.2.2. Key executives
  • 9.2.3. Company snapshot
• 9.3. Eli Lilly and Company
  • 9.3.1. Company overview
  • 9.3.2. Key executives
  • 9.3.3. Company snapshot
• 9.4. Bristol-Myers Squibb Co.
  • 9.4.1. Company overview
  • 9.4.2. Key executives
  • 9.4.3. Company snapshot
• 9.5. Teva Pharmaceutical Industries Ltd.
  • 9.5.1. Company overview
  • 9.5.2. Key executives
  • 9.5.3. Company snapshot
• 9.6. Impax Laboratories Inc.
  • 9.6.1. Company overview
  • 9.6.2. Key executives
  • 9.6.3. Company snapshot
• 9.7. Pfizer Inc.
  • 9.7.1. Company overview
  • 9.7.2. Key executives
  • 9.7.3. Company snapshot
• 9.8. UCB SA
  • 9.8.1. Company overview
  • 9.8.2. Key executives
  • 9.8.3. Company snapshot
• 9.9. Sun Pharmaceutical Industries Ltd.
  • 9.9.1. Company overview
  • 9.9.2. Key executives
  • 9.9.3. Company snapshot
• 9.10. Mylan Nv
  • 9.10.1. Company overview
  • 9.10.2. Key executives
  • 9.10.3. Company snapshot

관련자료